CPT Code Overview

CPT 81437 is used for genomic sequence analysis panels targeting hereditary colon cancer disorders, such as Lynch syndrome and PTEN hamartoma syndrome. This code requires sequencing of at least 10 genes, providing a comprehensive genetic assessment for individuals at risk of inherited colorectal cancer syndromes. The service type is genetic testing, and it is typically performed in a laboratory setting (POS 81). This testing plays a critical role in identifying genetic predispositions, guiding clinical management, and informing family risk assessments.

Clinical Context

A patient with a family history of colon cancer or a personal history of colon neoplasms presents to their healthcare provider. The provider, often a specialist in medical genetics, determines that the patient may be at risk for hereditary colon cancer syndromes such as Lynch syndrome or PTEN hamartoma syndrome. The provider orders a comprehensive genomic sequence analysis panel, which includes sequencing of at least 10 genes associated with hereditary colon cancer disorders. The specimen is collected and sent to a laboratory (Place of Service 81) for analysis. Results are interpreted by a medical geneticist, and the findings guide further management, surveillance, or genetic counseling for the patient and potentially their family members.

Coding Specifications

• Modifiers:

  • Modifier 26: Used to indicate the professional component of the service, typically when the provider is responsible for interpreting the genetic test results but not performing the laboratory analysis.
  • Modifier 59: Used to indicate a distinct procedural service, such as when multiple genetic tests are performed that are not normally reported together.

• Provider Taxonomies:

These taxonomies represent providers specializing in medical genetics, including both Ph.D. and M.D. clinical genetics, as well as clinical biochemical genetics.

Related Diagnoses

• Z80.0: Family history of malignant neoplasm of digestive organs

  • Indicates a patient with a family history of digestive organ cancers, supporting the need for hereditary cancer testing.

• C18.9: Malignant neoplasm of colon, unspecified

  • Used for patients diagnosed with colon cancer, which may prompt genetic testing for hereditary syndromes.

• Z85.038: Personal history of other malignant neoplasm of large intestine

  • Indicates a patient with a personal history of colon cancer, relevant for assessing genetic risk.

• D12.6: Benign neoplasm of colon, unspecified

  • Used for patients with benign colon tumors, which may warrant genetic evaluation if there is suspicion of hereditary syndromes.

• Z15.09: Genetic susceptibility to other malignant neoplasm

  • Indicates a patient with known genetic susceptibility to malignancies, supporting the use of comprehensive genetic testing.

Related CPT Codes

81435 is commonly used as an alternative to 81437 for smaller panels. The single gene codes (81292, 81295, 81298, 81301) may be used together or separately depending on the clinical scenario and are often included within the broader panel represented by 81437.

For CPT code 81437, the national mean rate for BUCA (average commercial) is $482.85, which is higher than the mean rates for Aetna ($387.97), UnitedHealth Group ($398.27), and Cigna ($503.13), but lower than Blue Cross Blue Shield ($684.80). Medicare rates are not available in the input for comparison.

Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Blue Cross Blue Shield shows the widest spread at $684.00, indicating substantial variability in rates. Cigna and BUCA also exhibit notable dispersion, with ranges of $412.00 and $355.92, respectively. UnitedHealth Group and Aetna have tighter ranges, at $237.00 and $160.00, respectively, suggesting more consistent reimbursement levels.

The table and chart below present the full breakdown of national benchmarks for each payer.